Weekly round-up: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with? Renee Aguiar-Lucander , former CEO of Calliditas Therapeutics , who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here , we tell the story of her remarkable seven-year journey with the firm.?

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours?

Novo Holdings , a leading global life science investor, on Tuesday announced that it had co-led a $181.4 million Series D financing in Alentis Therapeutics . Alentis is a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.?

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting? 2024?

Resolution Therapeutics , a clinical-stage biopharmaceutical company spun out of the University of Edinburgh pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases, on Monday announced new clinical and preclinical data highlighting the anti-inflammatory and anti-fibrotic effect of regenerative macrophage therapy. The data will be presented in oral and poster presentations at the?American Association for the Study of Liver Disease (AASLD) ?The Liver Meeting? 2024, which is being held in San Diego, California from 15-19 November 2024.?

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024?

STORM Therapeutics Limited (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, on Monday announced that it had presented promising data from its Phase 1 clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the?Society of Immunotherapy for Cancer (SITC) 39th?Annual Meeting , held in Houston, US, from 6-10 November 2024.?

Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting?

Vivet Therapeutics , a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, on Thursday announced that it will be presenting key pre-clinical findings for VTX-806 , its gene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at The Liver Meeting presented by the American Association for the Study of Liver Diseases (AASLD), being held in San Diego, CA from 15-19 November.?

Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX?

Minervax ApS , a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), on Thursday announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors.??

Xeltis announces FDA Breakthrough Device Designation for aXess and first patient treated in US pivotal trial?

Xeltis , a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, on Thursday announced that the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA ) has granted aXess Breakthrough Device Designation status. aXess is Xeltis’ vascular access conduit, which enables the creation of a new, permanent, living vessel for hemodialysis vascular access.?

Concurrently, following approval from the FDA, the first patient in aXess’ US-staged pivotal trial has now been enrolled and treated at the Flow Vascular Institute in Houston, Texas, by Dr. Karl Illig, marking a significant clinical milestone for Xeltis.?

Neuraxpharm reports another year of sustained growth and international expansion?

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, on Thursday marked the sixth anniversary since its rebranding as Neuraxpharm and its repositioning as a leading European CNS-focused pharma.?

Meet the Optimum Team at London Life Sciences week?

It’s that time of year again, when investors and biotech entrepreneurs descend upon London to attend one of the highlights of the industry calendar.?

LSX Inve$tival Showcase , and the Jefferies London Healthcare Conference give biotechs their chance to link with investors and update them about progress in their pipelines.?

And the European Lifestars Awards celebrate the greatest achievements in the sector over the past year. There’s also a host of receptions to attend. If you would like to meet one of the Optimum team please email [email protected] .?